Global Radiopharmaceuticals Market, By Type (Diagnostic, Therapeutic), Procedural Volumes (Diagnostic Procedures, Therapeutic Procedures), Application, Sources (Nuclear Reactors, Cyclotrons), End User, Geography (North America, Europe, APAC, South America, MEA)– Industry Trends and Forecast To 2024
The new market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.
The global radiopharmaceuticals market is segmented based on type, procedural volumes, application, sources, end-user, and geography.

On the basis of type, the global radiopharmaceuticals market is sub-segmented into diagnostic and therapeutic radiopharmaceuticals.

On the basis of procedural volumes, the global radiopharmaceuticals market is sub-segmented into diagnostic procedures and therapeutic procedures.

On the basis of application, the global radiopharmaceuticals market is sub-segmented into diagnostic application and therapeutic application. Diagnostic application are further sub-segmented into single-photon emission computed tomography (SPECT) and positron emission tomography (PET). Single-photon emission computed tomography (SPECT) includes cardiology, lymphoma, thyroid, neurology and others.

On the basis of sources, the global radiopharmaceuticals market is sub-segmented into nuclear reactors and cyclotrons.

On the basis of end user, the global radiopharmaceuticals market is sub-segmented into hospitals, ambulatory surgical centers, diagnostic centers, cancer research institutesand others.

Request for sample pages: http://databridgemarketresearch.com/reports/global-radiopharmaceuticals-market-trends-forecast-2024/

Based on geography, the market is segmented into 5 geographical regions, North America, Europe, Asia-Pacific, South America and Middle East and Africa. The geographical regions are further segmented into 29 major countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa and others. In 2017, North America is expected to dominate the radiopharmaceuticals market with more than 42.5%market share with a share of 4.7% followed by Europe and Asia-Pacific.


Read more: http://databridgemarketresearch.com/global-radiopharmaceuticals-market-poised-grow-8-7-till-2024/

Some of the major players operating in the global radiopharmaceuticalsmarket are Cardinal Health Inc., MallinckrodtPlc.,GE Healthcare, Lantheus Medical Imaging Inc., Bayer AG, Bracco Imaging SpA, Eczacibasi-Monrol Nuclear Products, Nordion Inc., Advanced Accelerator Applications S.A., IBA Molecular Imaging, CovidienPlc, Positron Corporation, NTP Radioisotopes Pty. Ltd., Advanced Medical Isotope Corporation, Avid Radiopharmaceuticals, Jubilant Pharma, Actinium Pharmaceuticals Inc., AREVA Meds,Immunomedics Inc., Merck& Co., Inc.,Navidea, PETNET Solutions Inc., Eckert & Ziegler, Siemens Healthcare, and Positron Corporation among others.

About Data Bridge Market Research:
Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.